← All causality assessments
Expected pharmacological effect
Causality assessment · Expected pharmacological effect
Haloperidol Decanoate and Weight Increased: is the FAERS signal real?
A written Bradford Hill assessment of one drug–event pair. The grade is a judgement about the signal, not a statement that this drug causes this event in any one person; FAERS counts are reports, not rates.
Haloperidol Decanoate ↔ Weight Increased
n=272 co-reports · PRR 9.4 · ROR 10.3
Clonazepam is a long-acting benzodiazepine. Drug abuse is the expected consequence of GABA-A modulation: tolerance, withdrawal. 2,159 co-reports (PRR 7.7) and Schedule IV status confirm abuse liability. The label carries a boxed warning for abuse, dependence, and withdrawal.
Boxed warning: clonazepam label (abuse/dependence/withdrawal). FDA PI.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 7.7 with 2,159 co-reports |
| Consistency | met | Reproduced across benzodiazepine class |
| Specificity | partial | Specific to GABA-A modulators |
| Biological gradient | met | Tolerance documented |
| Plausibility | met | GABA-A mechanism established |
| Coherence | met | Withdrawal standard |
| Experiment | n/a | Not an RCT endpoint |
| Analogy | met | All benzodiazepines class-wide |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✗ No ClinicalTrials.gov results-posting trial in the top search hits for Haloperidol captured weight increased as a tracked adverse event in a usable structure. Anxiolytic RCTs are short-term; abuse liability assessed in separate studies.